MrMugsy wrote: skippy1 wrote: STAY AWAY!!! WHEN THIS INVESTOR BUYS INTO A COMPANY, IT WILL NOT END WELL FOR MINORITY SHAREHOLDERS!!!! HIS OBJECTIVE IS TO TAKE OUT THE COMPANY AT A DISCOUNT. NEW INVESTORS END UP LOSING MONEY!!!
Thanks Skippy but I think your comment is too general for this specific case.
George made it clear he doesn't know the pharma space.
He also indicated that he respected this team and their abilities.
Finally, he is very confident that this team will make him money.
I am very much in agreement.
George is also very aware of how Goodman did it the first time. He knows it took Goodman 19 years with Paladin. The yardsticks are all there for George's comparison and I think he gets it.
There's a reason why the world didn't have a ROW before Knight.
There's a reason ENDO/Paladin really blew the lead in building a ROW.
George has been briefed on what it takes to become a ROW (I'm sure). He's been well briefed on the next leg of the strategy (I'm sure) ... and ... no wise investor is going to battle a successful team on their second go at it when we are this far along in only 7+ years.
7 years to ...
- get a starter artery across the Americas.
- build a powerful cash and investment position
- cashflow positive operation
- ready for the next leg of product growth (ROW as revenue multiplier) and additional ROW secondary arteries.
George is a very smart guy and he's not walking into something he doesn't understand (as an investment).
He also knows what happened to another 10% owner - who was for a lack of better words - a fish out of water with a bunch of investors who wanted something specific and who were not prepared to let one investor destroy that build.
So - many things for George to consider before he started accumulating in 2021.
Therefore, all I can say is ... Welcome aboard George - good to have you. Next !!!!
: )